The Food and Drug Administration is evaluating two potential drugs that could help keep people healthy after they’ve been infected with the coronavirus.
So far, there’s no clear system to make sure they would be allocated fairly or how to pay for these expensive drugs over the long haul.
“Demand is going to far outstrip supply here,” says Rena Conti at Boston University’s Questrom School of Business.
Even though manufacturers are gearing up to produce more than a million doses before the end of the year, some 50,000 Americans are getting infected every day, so the clamor for these drugs is likely to be considerable. (If the current pace of infection keeps up, there will be another 3.5 million infected Americans before the end of the year)….